«We showed that there are
markers on these stomach tumour cells that indicate they would be responsive to a type
of immunotherapy called immune checkpoint inhibitors, in particular anti-PDL1 immunotherapy, which is already used with
great success in the treatment
of melanoma and certain other cancers.